Literature DB >> 1382847

The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

E Weidmann1, T L Whiteside, R Giorda, R B Herberman, M Trucco.   

Abstract

To determine a possibly restricted T-cell receptor (TCR) repertoire in tumor-infiltrating lymphocytes (TIL) in response to tumor-associated antigens in patients with hepatocellular carcinoma (HCC), freshly isolated TIL (n = 5) and peripheral blood lymphocytes (PBL; n = 6; 3 paired with TIL) were studied for expression of TCR variable (V) beta regions. RNA purified from TIL or PBL was reverse-transcribed into complementary DNA. This complementary DNA was amplified by quantitative polymerase chain reaction with 22 primers specific for 20 TCR V beta gene families and a 3' constant (C) beta primer. As a reference for later quantitation, a fragment of TCR C alpha was coamplified with each V beta region. Using 32P-labeled 3' primers, the percentage of total V beta expression was calculated by measuring the cpm of each of the amplified products. In contrast to PBL of 6 control, healthy individuals, whose range of expression of each TCR V beta gene varied from 0 to 13%, the expression of some V beta genes in HCC TIL was as high as 33%, indicating a restricted TCR V beta usage in HCC TIL. When polymerase chain reaction-amplified complementary DNAs of the V beta 1 or V beta 3 genes obtained from two TIL preparations were cloned and sequenced, the same rearrangements were found in the majority of DNA clones. The particular V beta genes that were over- or underrepresented in TIL varied among the patients. In 3 of 6 PBL and 3 of 5 TIL, the V beta 3 gene was expressed with a relatively high frequency. The V beta 4 gene expression was consistently low in patients' TIL or PBL. In 3 paired PBL and TIL, V beta expression was similar. In 5 of 6 cases, HCC PBL had different TCR V beta frequencies from those seen in normal PBL. This analysis of TCR V beta usage in freshly isolated TIL and in PBL indicated that T-lymphocytes in patients with HCC might have restricted immunological reactivity and that V beta 3-restricted TIL might represent antitumor effector cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382847

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

3.  Quantitative analysis of T-cell receptor beta variable-gene usage in cutaneous late-phase reactions: implications for T-lymphocyte recruitment in cutaneous inflammation.

Authors:  S R Lessin; B M Benoit; G Li; A Moskovitz; B Zweiman
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

Review 4.  The genes influencing the susceptibility to IDDM in humans.

Authors:  S Faas; M Trucco
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

Review 5.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 6.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

7.  Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients.

Authors:  Sebastian Ochsenreither; Alberto Fusi; Susanne Wojtke; Antonia Busse; Natascha C Nüssler; Eckhard Thiel; Ulrich Keilholz; Dirk Nagorsen
Journal:  J Transl Med       Date:  2010-04-12       Impact factor: 5.531

8.  Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia.

Authors:  E Weidmann; J Brieger; B Jahn; D Hoelzer; L Bergmann; P S Mitrou
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

9.  T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer.

Authors:  M R Zocchi; M Ferrarini; N Migone; G Casorati
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

10.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.